

Wilm and Munoz-Chapuli

Tools for Wt1-based lineage tracing to analyse its role in embryonic development and normal organ homeostasis

Bettina Wilm¹ and Ramon Muñoz-Chapuli²

1 Department of Cellular and Molecular Physiology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

2 Department of Animal Biology, Faculty of Science, University of Malaga, Malaga, Spain

i. Summary / Abstract

The Wilms' tumour suppressor gene 1 (*Wt1*) is critically involved in a number of developmental processes in vertebrates, including cell differentiation, control of the epithelial/mesenchymal phenotype, proliferation and apoptosis. *Wt1* proteins act as transcriptional and post-transcriptional regulators, in mRNA splicing and in protein-protein interactions. Furthermore, *Wt1* is involved in adult tissue homeostasis, kidney function and cancer. For these reasons, *Wt1* function has been extensively studied in a number of animal models to establish its spatiotemporal expression pattern and the developmental fate of the cells expressing this gene. In this chapter, we review the developmental anatomy of *Wt1*, collecting information about its dynamic expression in mesothelium, kidney, gonads, cardiovascular system, spleen, nervous system, lung and liver. We also describe the adult expression of *Wt1* in kidney podocytes, gonads, mesothelia, visceral adipose tissue and a small fraction of bone marrow cells. We have reviewed the available animal models for *Wt1*-expressing cell lineage analysis, including direct *Wt1* expression reporters and systems for permanent *Wt1* lineage tracing, based on constitutive or inducible Cre recombinase expression under control of a *Wt1* promoter. Finally we provide a number of laboratory protocols to be used with these animal models in order to assess reporter expression.

ii. Key words

Wt1, Wilms' tumour suppressor gene, cell lineage tracing.

1. **Introduction**

Developmental anatomy of *Wt1*

The Wilms' tumour suppressor gene 1 (*Wt1*) is well known for its dynamic expression pattern during embryonic development, both in mouse and human. The gene gives rise to at least 24 protein isoforms in human, that are involved in regulation of expression of target genes acting in tissue development, growth, differentiation, and apoptosis. Target gene expression is frequently regulated through binding to co-regulators. Furthermore, *Wt1* proteins also act as post-transcriptional regulators in mRNA splicing and in protein-protein interaction (1).

In this chapter, we first give a short overview of the distribution of *Wt1* expression at gene and/or protein level during development in mice and other animal models, and describe the adult expression of *Wt1*. We then review the murine models available for the study of *Wt1* function, and provide protocols that include the use of some of these models, with special emphasis on *Wt1*-expressing cell lineage tracing (in short: *Wt1* lineage tracing).

Mesothelium:

The mesothelium is a simple epithelium that lines the coelomic cavities and the organs that develop within these cavities. It forms from the lateral mesoderm at around E9 in the mouse embryo. By this time *Wt1* transcripts start to be detected in the parietal coelomic lining, and over the heart, intestine and urogenital ridge (2). Expression of *Wt1* protein appears first over the urogenital ridge at E9.5, but between E10.5 and E11.5 *Wt1* protein is present in the mesothelial layers of the parietal coelomic linings, over the heart, intestine, lungs and liver, and also in the septum transversum and developing diaphragm (3-7). *Wt1* is

also found in many submesothelial mesenchymal cells in the parietal layers of the coelom at later stages of development (8).

Kidney:

Expression analysis of the murine *Wt1* gene in the developing kidney by *in situ* hybridisation and immunohistological analysis revealed that *Wt1* mRNA/Wt1 protein is expressed in the urogenital ridge from E9, the pro- and mesonephric tissues from E10, and the metanephric mesenchyme (MM) from E12 (9,10). The functional postnatal kidney develops from two tissues that have their origin in the intermediate mesoderm, the metanephric mesenchyme and the ureteric bud (UB). Reciprocal induction events between MM and UB lead to the formation of the functional kidney. This involves several rounds of induction and branching events, involving MM condensation into the mesenchymal cap around the UB, and a subsequent differentiation of condensed cap mesenchyme via mesenchymal-to-epithelial transition (MET) into epithelial cells forming the nephron. Expression of *Wt1* in metanephric structures is highly dynamic with highest levels of expression in the condensing cap mesenchyme, comma- and s-shaped body of the developing nephrons, and finally remaining restricted to the podocytes of the glomeruli (11-13). This was confirmed in transgenic mice expressing LacZ under control of YAC fragments that harboured the human *WT1* gene locus including flanking regions of 470 or 280kb (14). *Wt1* expression is not found in the UB.

Specifically, *Wt1* is intimately involved in the regulation of the early steps of nephron formation and the maintenance of the glomeruli, through interactions with a range of nephrogenic and renal proteins. *Wt1* regulates kidney development from early stages leading to complete renal agenesis in loss of *Wt1* mutants through apoptosis of the

mesonephric tubules and the metanephric mesenchyme, resulting in failure to induce ureteric bud outgrowth (15). Apoptosis of renal progenitors in absence of *Wt1* has recently been related with downregulation of fibroblast growth factor and induction of BMP/pSMAD signalling, and this apoptosis can be rescued by recombinant FGFs or inhibition of pSMAD signalling (16). Analysis of subsequent stages of kidney development, which is precluded due to metanephric apoptosis in the *Wt1* null mutants, has been performed using kidney organoid culture in combination with siRNA approaches (17), and conditional inactivation of *Wt1 in vivo* (18). These studies showed that *Wt1* controls MET to allow formation of renal vesicles and subsequent stages towards nephron formation from MM, through control of *Wnt4* expression. *Wnt4* has been identified as a crucial regulator of MET during nephron formation (19,20). Furthermore, a specific role for *Wt1* in the control of *Wnt4* expression had been described since *Wt1* expression precedes that of *Wnt4*, *Wt1* can control *Wnt4* expression *in vitro*, and *Wnt4* expression is lost in the embryonic kidney mesenchyme when *Wt1* is inactivated (18, 21,22).

At later stages, *Wt1* protein controls formation of the podocytes and their homeostasis through transcriptional regulation of *Pax2*, *Nephrin* and *Podocalyxin* (13, 23-26).

Wt1 also regulates expression of *Nestin*, an intermediate filament protein, in the glomeruli, although the significance of *Nestin* expression in the kidney is not well understood (27). Conditional deletion of *Wt1* in embryonic kidneys using a *Nestin-Cre* model leads to a failure in MET and nephron formation (18).

Using CHIP-PCR to identify *Wt1* target sites *in vivo*, a recent systemic study demonstrated that a range of factors important for kidney development are transcriptional targets of *Wt1*, including *Bmp7* and *Sall1* (28). Taken together, recent studies in the developing kidney have

shown that Wt1 is a key regulator of a range of molecular pathways that lead to the formation of functional nephrons from the metanephric mesenchyme.

Gonads:

Gonads develop from the urogenital ridge, initially as indifferent primordia, but later they specify into testis and ovaries. They start to arise at around E11 from the mesonephros, the embryonic kidney that forms only transiently, and the overlying coelomic mesothelium. The coelomic mesothelial cells contribute to gonad formation by migrating into the gonadal ridge, forming the primary sex cords and later giving rise to the Sertoli cells (male) or granulosa cells (female) (29, 30). In situ hybridisation and immunohistochemical studies have shown that Wt1 is expressed in the mesonephros and the overlying coelomic epithelium from around E10, but as the urogenital ridges thicken during gonad formation, Wt1 is strongly expressed in the mesenchymal component (12, 13).

Development into male or female gonads and genital organs is regulated by Sry expression, leading to testes formation and differentiation of the Wolffian ducts into seminal vesicles, epididymis and vas deferens in the male, or ovary formation and the emergence of the oviducts, Fallopian tubes, uterus and upper vagina from the Müllerian ducts in the female. However, most components of the testis arise from mesonephric cells migrating into the gonad, including peritubular and vascular endothelial cells, while the Leydig cells are formed in several waves from primary mesonephric and mesonephric-derived cells (31-33). One can speculate that since Wt1 is expressed in the gonadal anlagen from early on, most gonadal cells have their origin in cells originally expressing Wt1.

Testis: A complex hierarchical cascade of transcription and signalling factors controls the formation and maintenance of the male gonads. *Wt1* is involved in this cascade at several levels since *Wt1* expression is required for the survival of the early gonadal anlagen (34). A range of studies have shown that *Wt1* is an important regulator of sex determination by controlling the expression of the *Sry* gene (34-39). Loss of function studies have demonstrated that *Wt1* regulates the expression of steroidogenic factor 1 (*Sf1*) in the indifferent gonad (40). In addition, molecular and *in vitro* data indicate that *Wt1* acts in concert with *Sf1* to regulate the expression of the Müllerian inhibiting substance (*MIS*, also called anti-Müllerian hormone, AMH) (41), and it probably indirectly activates *Dax1* during early gonadal development (42).

Using a mouse model for testis-specific conditional ablation of *Wt1*, Vicky Huff and collaborators showed that *Wt1* is required for the formation and maintenance of the seminiferous tubules, Sertoli cells and germ cells in the testicular cords (43). Specifically, proteins expressed in Sertoli cells including *Sox8*, *Sox9* and *MIS* were lost when *Wt1* function was abolished. Importantly, loss of *Wt1* in the testes leads to β -catenin accumulation which in turn results in testicular cord disruption (44). Further evidence for a role of *Wt1* in testicular cord and Sertoli cell maintenance and germ cell survival stems from the finding that testicular cord integrity is associated with expression of *Col4a1* and *Col4a2* as these collagens are downregulated in the testes of mice with testis-specific loss of *Wt1* (45). Using an siRNA approach and transgenic mice expressing dominant negative *Wt1*, similar results were reported, supporting an essential role for *Wt1* in Sertoli cell and germ cell integrity and survival (46).

Ovary: During female gonad development, *Wt1* is expressed in stromal cells, granulosa cells and the overlying coelomic mesothelium of the ovary (10). Specifically, granulosa cells of the primordial, primary and secondary follicles express *Wt1* during ovary development, and expression is maintained throughout adult life (47), suggesting that *Wt1* is involved in folliculogenesis.

Germ cells: *Wt1* is expressed in germ cells when they start converting from primary germ cells to gonadal germ cells, beginning at embryonic day E11.5. Chimera experimentation has shown that loss of *Wt1* in ES cells leads to their exclusion from the germ cell lineage, suggesting that *Wt1* is involved in germ cells proliferation, maturation or survival (48).

Heart and blood vessels:

Wt1 expression in the heart is predominantly, but not exclusively, associated with epicardial development. The earliest expression of *Wt1* during cardiac morphogenesis is detected in mouse embryos at E9.5 in the proepicardium, which is the epicardial primordium; subsequently, *Wt1* expression continues during the epicardial covering of the heart (2, 49). *Wt1* expression is maintained in the epicardial-derived mesenchymal cells (EPDC) which delaminate from the epicardium and invade first the subepicardial space, and then the myocardium. This expression is progressively downregulated as EPDC differentiate and contribute to the vascular and connective tissue of the heart.

The role played by *Wt1* in the developing epicardium seems to be critical, since conditional *Wt1* loss of function in this tissue leads to impaired generation of EPDC, abnormal coronary morphogenesis and thinning of the myocardium, resulting in embryonic lethality (50). The

mechanism by which *Wt1* acts in the epicardium is not completely understood, but results from recent studies suggest that the balance between Snail and E-cadherin activity (50) and the canonical β -catenin pathway (51) serve as main downstream effectors of *Wt1* in regulating epicardial to mesenchymal transition. Additionally, recent data indicate that in the epicardium *Wt1* regulates the transcriptional activation of *Raldh2*, which represents the main retinoic acid synthesising enzyme in mesodermal tissues (52). It had been previously established that cross-talk between epicardium and myocardium, facilitating development of both components, is dependent on retinoic acid signaling (53, 54).

Other genes activated by *Wt1* in the epicardium include the neurotrophin receptor *TrkB* (55) and *$\alpha 4$ integrin*, required to maintain epicardial adhesion to the myocardium (56). *Wt1* regulates expression of the erythropoietin receptor (57) in hematopoietic cells and its ligand erythropoietin in *in vitro* assays (58). Since the erythropoietin signaling system also acts in the epicardium and its failure causes myocardial thinning (59), *Wt1* may also be involved through this pathway in epicardial-myocardial interaction, thus supporting development and differentiation of both tissues. Finally, an unsuspected role of *Wt1* in the developing epicardium is the regulation of the expression of some chemokines. Specifically, *Wt1* down-regulates *Ccl5* and *Cxcl10*, two chemokines that inhibit EPDC migration and myocardial proliferation. This role is performed through increasing of the levels of *Irf7* (60).

In summary, in the epicardium *Wt1* activates a set of genes related with epicardial adhesion, epithelial-mesenchymal transition and migration. Thus, *Wt1* represents a key gene for epicardial development and function.

Wt1 expression has also been found in non-epicardial derived, cardiac cells. A few cells expressing Wt1 are already present in the endocardium and possibly in the myocardium of E9.5 embryos (61).

Lineage tracing studies of Wt1-expressing cells using Cre-LoxP technology have shed further light onto the role of Wt1 during cardiovascular development and function. Importantly, these studies have shown that the fate of Wt1-expressing cells in the heart is clearly related to coronary vascularization and the formation of cardiac connective tissue. Specifically, Wt1-lineage studies have confirmed an extensive contribution to coronary smooth muscle and cardiac fibroblasts (62). EPDC-derived Wt1-expressing cells have also been shown to contribute to the lateral atrioventricular cushions where they differentiate into fibroblastic cells of the valves (63). However, contribution of Wt1-expressing cells to coronary endothelium has been more controversial. Using different lineage tracing approaches, it was shown that the proportion of coronary endothelial cells originating from Wt1-expressing cells comprises less than 15% (3, 62). Recent data (Cano et al., submitted) demonstrate a large, but not complete, overlap between the Wt1 lineage and a *bona fide* epicardial-derived lineage characterized by the activation of a Gata4 enhancer in the septum transversum and proepicardium. These epicardial-derived cells contribute to a minor, but significant fraction of the coronary endothelium (about 20% of all the endothelial cells), at least during embryonic life and early postnatal stages. This agrees with recent findings reporting that the endocardium is a major contributor to the coronary endothelium (64, 65). Wagner and colleagues showed that Wt1 is expressed in the coronary endothelium of late gestation mouse embryos, while Wt1^{-/-} embryos that survive to close to term, reveal a dramatic lack in coronary vasculature (55). In addition, the group could identify the neurotrophin receptor TrkB as a downstream target of Wt1 in the coronary endothelium

(55), and argued that loss of the coronary vasculature in *Wt1* mutant embryos was directly linked to down-regulation of *TrkB* expression.

Furthermore, using *in vitro* experiments, *Wt1* was shown to bind to the VEGF promoter and regulate its expression (66, 67). The intermediate filament and progenitor marker Nestin has also been shown to be downstream of *Wt1* in the developing coronary vasculature (27), and to be co-expressed the vasa vasorum of human tissue samples (68). The finding that *Wt1* regulates VE-cadherin expression *in vitro* and *in vivo* since VE-cadherin expression is reduced in the liver and hearts of *Wt1* mutant embryos (69), corroborates the hypothesis that *Wt1* is important for the regulation of blood vessel formation.

Lineage tracing studies have also added to controversy around the contribution of *Wt1*-expressing cells to the myocardium. Of note, this hypothetical contribution may originate from two sources, i) the EPDC and ii) migration of myocardial progenitors from the posterior secondary cardiac field, where *Wt1* expression is prominent in mesenchymal cells of the transverse septum. Original evidence for *Wt1*-derived myocardial cells provided by Zhou et al. (62) was questioned by Rudat and Kispert (61) on the basis of the unsuitability of the Cre drivers used. Zhou and Pu (70) responded by providing new validating evidence for the existence of cardiomyocytes derived from *Wt1*-expressing cells, which they considered as epicardial-derived. On the other hand, the existence of a sinus venosus defect in *Wt1*-deficient mouse embryos (8) could be interpreted as the lack of a *Wt1* lineage population contributing to the inflow tract myocardium. This possibility was ruled out by Norden et al. (8) who, by using two different models (LacZ reporter and *Wt1*-Cre) found that *Wt1*-expressing cells did not give rise to myocardial cells. These authors conclude that the involvement of the *Wt1*-lineage in sinus venosus development seems to be indirect.

Developmental haematopoiesis:

Molecular evidence for Wt1 as a regulator of developmental haematopoiesis is based on studies showing that Wt1 regulates expression of both Epo and its receptor EpoR in the fetal liver as the primary haematopoietic organ during mid-gestation (57,58). Furthermore, loss of Wt1 affects *in vitro* differentiation of fetal liver cells, suggesting that Wt1 regulates possibly in synergy with EpoR the differentiation potential of fetal haematopoietic stem cells (57). However, transplantation studies into lethally irradiated mice showed that fetal liver-derived Wt1^{-/-} haematopoietic stem cells were as potent in restoring bone marrow and peripheral blood cells as wild type cells (71).

Spleen:

Wt1 is expressed in the spleen rudiment of the dorsal mesogastrium of mouse embryos by E10.5, continuing in the spleen capsule and epithelium by E14.5 (12). Herzer et al. (72) reported expression by E12.5 and described failure of spleen development in Wt1^{-/-} embryos. Koehler et al. (73) found that the expression of Wt1 in the spleen follows that of Hox11 (a homeobox gene required for spleen development) with a delay of one day, while Hox11^{-/-} embryos show reduced expression of Wt1 in the spleen rudiment, suggesting that Wt1 is acting downstream of Hox11 in spleen development.

Body muscle:

Expression of Wt1 in musculature of the body wall of E12-E13 mice embryos was described by Armstrong et al. (2), but this observation has not been confirmed by further reports. It is possible that the presence of mesenchymal cells migrating from the dorsolateral coelomic epithelium to the lateral body wall is related with this early description.

Nervous system and eye:

Besides its extensive expression in mesodermal cells, there are only a few specific domains of Wt1 expression in the neuroectoderm. In mouse embryos, Wt1 is expressed from E11 in a narrow linear domain located between the mantle and the ependymal layers. This expression domain becomes more pronounced by E12 and expands by E13 before turning more diffuse, extending to the ventral part of the marginal area of the medulla and finally disappearing at the end of gestation (2, 12, 14). This expression is anatomically related to the area where motoneurons differentiate. A second area of expression is found in the roof of the 4th ventricle, in a diverticulum of the ependymal layer, close to the rostral part of the medulla oblongata (2, 12).

Wt1 is also expressed in developing retina, as shown by RT-PCR in E12.5 mice embryos. In humans, retina expression of Wt1 has been detected in day 42 fetuses (2). Wt1 seems to be required for retinal development since Wt1-deficient mouse embryos show defects in retinal ganglion cells (74). This effect could be due to the activation of Pou4f2, a transcription factor essential for survival of retinal ganglion cells.

Lung:

Wt1 is expressed in mesothelial cells of the murine lungs from the early sprouting of the lung buds onwards (6, 12, 75). Differently to the heart, Wt1 is rapidly down-regulated in cells delaminating from the mesothelium and incorporating into the pulmonary mesenchyme. These mesothelial-derived cells contribute to most pulmonary mesodermal tissues, including vascular and bronchial smooth muscle, tracheal cartilage and a small fraction of the vascular endothelium (6, 75). In neonates, about 1.5% of all the dissociated pulmonary cells and about 11% of all the endothelial cells derive from the Wt1-expressing cell lineage (6). Another difference with the epicardium is that the migration of the mesothelial-derived cells inside the pulmonary stroma is dependent of hedgehog signaling (5).

Liver:

Wt1 is expressed in the liver mesothelium from of the early stages of hepatic development (2, 14). Liver mesothelial cells continue to express Wt1 when they migrate from the surface and intermingle with the hepatoblasts and the hematopoietic cells to differentiate into sinusoidal endothelium and stellate cells (14). In contrast to the heart and the lung, in the liver Wt1 is not down-regulated with onset of differentiation of mesothelium-derived cells. In fact, Wt1 expression is still detectable in sinusoidal endothelial cells (14). This invasion of mesothelial derived cells is necessary for proper hepatic development (76, 77).

Adult expression of Wt1:

Wt1 expression has been reported in a few sites of adult mice, namely kidney podocytes, Sertoli cells of the testes, granulosa cells of the ovary, mesothelia, pancreatic stellate cells,

the stromal vascular component of several fat bodies including visceral adipose tissue progenitors, and a small fraction of bone marrow cells (3, 78-80).

The podocytes are the most prominent site of adult Wt1 expression, and in fact podocyte maintenance and function depends on Wt1 (80). In postnatal stages, Wt1 is involved in the regulation of the maintenance of the glomerular filtration function of the kidney, as shown through a range of studies. Mice with reduced Wt1 expression and subsequent downregulation of nephrin and podocalyxin expression showed increased glomerulosclerosis (26). The damage to the glomeruli is possibly caused by insufficient levels of podocalyxin and nephrin both of which are required for the functional morphology of the slit diaphragm and foot processes of the glomerular filtration membrane. Furthermore, recent study from the Ai lab has shown that Wt1 is important for maintaining cross-talk between podocytes and glomerular endothelial cells across glomerular filtration membrane. Specifically, Wt1 controls the expression of the 6-O-endosulfatases Sulf1 and Sulf2 which in turn regulate signalling of VEGFA from podocytes to glomerular endothelial cells across the glomerular filtration barrier (81).

Wt1 expression is not maintained in all adult mesothelial tissues: while it is present in the adult intestine (3) and the mesothelium lining the visceral fat (78, 79), there are conflicting findings about Wt1 expression in the lung mesothelium, with Dixit and colleagues reporting downregulation of Wt1 in postnatal and adult mice, while Que and colleagues have shown continued expression in P45 animals (5, 79). Karki et al. (82) also stated that expression of Wt1 remains in the adult pulmonary mesothelium, and its loss is correlated with mesenchymalization and fibrosis. Wt1 expression in the liver mesothelium seems to be

downregulated after E13.5 (77). It is possible that a low basal level of Wt1 expression in adult mesothelium is the basis for these discrepancies.

The expression of Wt1 in the visceral fat mesothelium and in the progenitors of the visceral white adipose tissue (WAT) establishes a key difference with other fat bodies such as subcutaneous WAT and brown adipose tissue that do not develop from Wt1-expressing cells (79). This difference could be significant given the different potential of visceral and subcutaneous WAT as risk factor for a number of diseases.

Expression of Wt1 is maintained into adulthood in the Sertoli and granulosa cells (2, 10). Wt1 regulates Sertoli cell polarity in the testes, and it is essential for germ cell survival, differentiation and spermatogenesis (83, 84). Additionally, the expression of Wt1 in Sertoli cell is essential to maintain steroidogenesis in Leydig cells (85, 86). In the ovary, Wt1 is also expressed in granulosa cells, controlling their polarity and differentiation (87). In a mouse model mimicking the Denys-Drash Syndrome (DSS), heterozygous mice have reduced ovulation rates, premature differentiation of granulosa cells, leading to disturbed development of follicles (87). This study supports the notion that Wt1 is not only required for normal spermatogenesis, but also for oogenesis.

Besides the ovary, Wt1 expression has also been reported in the embryonic and adult uterus, specifically the myometrium and human endometrium (10, 88, 89).

Wt1 expression was detected in the bone marrow of mice and humans for the first time by Fraizer et al. (90). A range of studies showed that Wt1 expression in hematopoietic cells is restricted to the phase of expansion of hematopoietic progenitor cells while expression was found to be reduced in mature haematopoietic cells and absent in the mature peripheral blood (91, and references therein). Furthermore, it was found that Wt1 expression was

downregulated in haematopoietic cell lines that underwent differentiation, while high expression of Wt1 was correlated with induced proliferation of cells in culture (92, 93). Wt1 seems to have conflicting roles in different stages of haematopoiesis since it can induce quiescence in early (CD34+ CD38-) progenitors, while it stimulates differentiative behaviour in more committed progenitor cells. Wt1 is present in erythroblastic progenitors, where it transactivates the EPO receptor (56). Wt1 is also involved in granulocyte differentiation (94). Single cell qPCR of cells during haematopoiesis revealed a biphasic expression pattern with high activity in quiescent primitive precursor cells and specific myeloid cell populations (95,96). Interestingly, using a genetically modified mouse line which expresses GFP under control of the endogenous Wt1 locus, Hosen and colleagues came to a slightly different finding, since in Wt1^{GFP/+} mice, Wt1 expression was absent or very low in haematopoietic stem cells or fully differentiated granulocytes, respectively, while expression was higher in myeloid progenitor cells (97). Loss of Wt1 in haematopoietic stem cells was shown to affect their differentiation potential (98). Furthermore, in an independent study using ES cells lacking Wt1 protein that were differentiated towards the haematopoietic lineage, similar observations were made, as the colony forming/differentiation potential of the cells was greatly reduced (99). The authors could show that Wt1^{-/-} ES cells undergo apoptosis that is dependent of Vegfa, and that Wt1 is responsible for splicing of Vegfa into functional isoforms. The function of Wt1 in blood cell differentiation could be mediated by p21cip1 induction, leading to growth arrest (95). This would explain the role played by Wt1 mutations in leukemogenesis (see below).

In some pathological conditions, the adult expression of Wt1 becomes more prominent. Wt1 is expressed in coronary arteries (endothelium and smooth muscle) after myocardial infarction (100). This is probably due to the hypoxia produced by the local ischemia, since

the upregulation of the *Wt1* gene, mediated by a hypoxia responsive element in the *Wt1* promoter, is mimicked by exposing rats to hypoxic conditions (101). Thus, low oxygen tension could be a driver for *Wt1*-regulated angiogenesis (102).

Wt1 was named after its supposed role in the development of Wilms' tumor (103), although only a fraction of these tumours shows alterations in *WT1* expression. In contrast, abnormal overexpression of *WT1* has been reported in a number of tumour cells (104), and it is particularly prominent in acute myeloid leukemia (AML) (105-107). *WT1* is overexpressed in malignant cells of 90% of patients with AML and appears mutated in approximately 10% of these patients (108). Importantly, these observations have raised expectations for *Wt1* as a target in cancer immunotherapy (109, 110).

Wt1 expression in non-mammalian animal models:

The developmental expression of *Wt1* in chicken embryos is in principle similar to that described for mammals (111). *Wt1* has been used as a marker of proepicardial, epicardial and epicardial-derived cells by a number of groups studying chick development (112-116).

In zebrafish, two *Wt1* genes, *wt1a* and *wt1b*, have been reported, both showing +KTS and -KTS isoforms (117). In early embryos the expression of both genes is dynamic and restricted to intermediate mesoderm. Expression of *wt1a* in the zebrafish pronephros is regulated by retinoic acid through a highly conserved enhancer (118). In addition, *wt1a* has recently been reported to regulate expression of *osr1*, thus controlling the differentiation of zebrafish podocytes (119). The expression domains of *wt1a* and *wt1b* in adult fish tissues are more extensive than in mammals, including gonads, kidneys, heart, spleen and muscle. Both *wt1a* and *wt1b*, have also been reported in other fish, such as *Oncorhynchus*, *Oryzias*, *Takifugu*

and *Tetraodon* (reviewed in 120). In *Tetraodon*, the highly conserved motif KTS, distinguishing DNA-binding to DNA non-binding isoforms, is changed to KPS (120).

Information on Wt1 expression in amphibians is more limited. Wt1 is expressed in Sertoli cells, spermatogonia and mature sperm stages in the testes of the newt *Cynops pyrrhogaster* (121). In *Xenopus*, Wt1 expression is first restricted to the developing nephric system, and later is also detected in the developing heart (122, 123). Since Wt1 is not detected in developing pronephric tubules and ducts, its function seems to be related with the development of the glomeruli. In fact, when Wt1 was ectopically expressed in *Xenopus* embryos by mRNA injection, it inhibited pronephric tubule development (124).

Regarding invertebrates, a Wt1 ortholog has been found in the cephalochordate *Branchiostoma floridae* (125). Furthermore, the *Drosophila* gene *Klumpfuss* has been considered as a Wt1 ortholog, and is involved in neuronal (126, 127) and hemocyte differentiation (128). However, despite the similarity between the four zinc-finger domains with those of the vertebrate Wt1, the N-terminal region is clearly different making this orthology very doubtful.

Details of animal model systems and approaches to study systemic and inducible loss of function of Wt1 will be described in [Chapter XYZ](#).

References

- 1 Toska E., Roberts S.J. 2014 Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1). *Biochem J* **461**, 15-32
- 2 Armstrong J.F., Pritchard-Jones K., Bickmore W.A. et al. 1993 The expression of the Wilms' tumour gene, WT1, in the developing mammalian embryo. *Mech Dev* 1993 **40**, 85-97
- 3 Wilm B., IJpenberg A., Hastie N.D., et al. 2005 The serosal mesothelium is a major source of smooth muscle cells of the gut vasculature. *Development* **132**, 5317-5328
- 4 Asahina K., Zhou B., Pu W.T. et al. 2011 Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. *Hepatology*. **53**, 983-995
- 5 Dixit R, Ai X, Fine A 2013 Derivation of lung mesenchymal lineages from the fetal mesothelium requires hedgehog signaling for mesothelial cell entry. *Development* 2013 **140**, 4398-406
- 6 Cano E., Carmona R., Muñoz-Chápuli R. 2013 Wt1-expressing progenitors contribute to multiple tissues in the developing lung. *Am J Physiol - Lung Cell Mol Physiol* **305**, L322–332
- 7 Carmona R., Cano E., Mattiotti A., et al. 2013 Cells derived from the coelomic epithelium contribute to multiple gastrointestinal tissues in mouse embryos. *PLoS One* **8**:e55890.
- 8 Norden J., Grieskamp T., Lausch E., et al. 2010 Wt1 and retinoic acid signaling in the subcoelomic mesenchyme control the development of the pleuropericardial membranes and the sinus horns. *Circ Res* **106**, 1212-1220

9 Buckler A.J., Pelletier J., Haber D.A. et al. 1991 Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. *Mol Cell Biol* **11**,1707-1712.

10 Pelletier J., Bruening W., Li F.P. et al. 1991 WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. *Nature* **353(6343)**:431-434.

11 Armstrong J.F., Kaufman M.H., van Heyningen V. et al. 1993 Embryonic kidney rudiments grown in adult mice fail to mimic the Wilms' phenotype, but show strain-specific morphogenesis. *Exp Nephrol* **1**, 168-74.

12 Rackley R.R., Flenniken A.M., Kuriyan N.P. et al. 1993 Expression of the Wilms' tumor suppressor gene WT1 during mouse embryogenesis. *Cell Growth Differ* **4**, 1023-1031.

13 Ryan G., Steele-Perkins V., Morris J.F. et al. 1995 Repression of Pax-2 by WT1 during normal kidney development. *Development* **121**, 867-875

14 Moore A.W., Schedl A., McInnes L. et al. 1998 YAC transgenic analysis reveals Wilms' tumour 1 gene activity in the proliferating coelomic epithelium, developing diaphragm and limb. *Mech Dev* **79**, 169-184

15 Kreidberg J.A., Sariola H., Loring J.M. et al. 1993 WT-1 is required for early kidney development. *Cell* **74**,679-691

16 Motamedi F.J., Badro D.A., Clarkson M. et al. 2014 WT1 controls antagonistic FGF and BMP-pSMAD pathways in early renal progenitors. *Nat Commun* **5**:4444

- 17 Davies J.A., Lodomery M., Hohenstein P. et al., 2004 Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiation. *Hum Mol Genet* **13**, 235-246
- 18 Essafi A., Webb A., Berry R.L. et al. 2011 A wt1-controlled chromatin switching mechanism underpins tissue-specific wnt4 activation and repression. *Dev Cell* **21**, 559-574
- 19 Stark K., Vainio S., Vassileva G. et al. 1994 Epithelial transformation of metanephric mesenchyme in the developing kidney regulated by Wnt-4. *Nature* **372(6507)**:679-683.
- 20 Kispert A., Vainio S., McMahon A.P. et al. 1998 Wnt-4 is a mesenchymal signal for epithelial transformation of metanephric mesenchyme in the developing kidney. *Development* **125**, 4225-4234
- 21 Sim E.U., Smith A., Szilagi E. et al. 2002 Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1. *Oncogene* **21**, 2948-2960.
- 22 Murugan S., Shan J., Kühl S.J. et al. 2012 WT1 and Sox11 regulate synergistically the promoter of the Wnt4 gene that encodes a critical signal for nephrogenesis. *Exp Cell Res* **318**, 1134-1145
- 23 Guo G., Morrison D.J., Licht J.D. et al. 2004 WT1 activates a glomerular-specific enhancer identified from the human nephrin gene. *J Am Soc Nephrol* **15**, 2851-2856
- 24 Wagner N., Wagner K.D., Xing Y. et al., 2004 The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1. *J Am Soc Nephrol* **15**, 3044-3051

25 Palmer R.E., Kotsianti A., Cadman B. et al., 2001 WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. *Curr Biol* **11**, 1805-1809

26 Guo J.K., Menke A.L., Gubler M.C. et al., 2002 WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. *Hum Mol Genet* **11**, 651-659

27 Wagner N., Wagner K.D., Scholz H. et al. 2006 Intermediate filament protein nestin is expressed in developing kidney and heart and might be regulated by the Wilms' tumor suppressor Wt1. *Am J Physiol Regul Integr Comp Physiol* **291**, R779-787

28 Hartwig S., Ho J., Pandey P. et al. 2010 Genomic characterization of Wilms' tumor suppressor 1 targets in nephron progenitor cells during kidney development. *Development* **137**, 1189-1203

29 Albrecht K.H., Eicher E.M. 2001 Evidence that Sry is expressed in pre-Sertoli cells and Sertoli and granulosa cells have a common precursor. *Dev Biol* **240**, 92-107

30 Karl J, Capel B. 1998 Sertoli cells of the mouse testis originate from the coelomic epithelium. *Dev Biol* **203**, 323-333

31 Capel B., Albrecht K.H., Washburn L.L. et al. 1999 Migration of mesonephric cells into the mammalian gonad depends on Sry. *Mech Dev* **84**, 127-131

32 Martineau J., Nordqvist K., Tilmann C. et al. 1997 Male-specific cell migration into the developing gonad. *Curr Biol* **7**, 958-968

33 Tilmann C., Capel B. 1999 Mesonephric cell migration induces testis cord formation and Sertoli cell differentiation in the mammalian gonad. *Development* **126**, 2883-2890

34 Hammes A., Guo J.K., Lutsch G. et al. 2001 Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. *Cell* **106**, 319-329

35 Shimamura R., Fraizer G.C., Trapman J. et al. 1997 The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor. *Clin Cancer Res* **3**:2571-2580

36 Hossain A., Saunders G.F. 2001 The human sex-determining gene SRY is a direct target of WT1. *J Biol Chem* **276**, 16817-16823

37 Matsuzawa-Watanabe Y., Inoue J., Semba K. 2003 Transcriptional activity of testis-determining factor SRY is modulated by the Wilms' tumor 1 gene product, WT1. *Oncogene* **22**, 7900-7904.

38 Miyamoto Y., Taniguchi H., Hamel F. et al. 2008 A GATA4/WT1 cooperation regulates transcription of genes required for mammalian sex determination and differentiation. *BMC Mol Biol* **9**:44

39 Bradford S.T., Wilhelm D., Bandiera R. et al. 2009 A cell-autonomous role for WT1 in regulating Sry in vivo. *Hum Mol Genet* **18**, 3429-3438

40 Wilhelm D., Englert C. 2002 The Wilms tumor suppressor WT1 regulates early gonad development by activation of Sf1. *Genes Dev* **16**, 1839-1851

41 Nachtigal M.W., Hirokawa Y., Enyeart-VanHouten D.L. et al. 1998 Wilms' tumor 1 and Dax-1 modulate the orphan nuclear receptor SF-1 in sex-specific gene expression. *Cell* **93**, 445-454

42 Kim J., Prawitt D., Bardeesy N. et al. 1999 The Wilms' tumor suppressor gene (wt1) product regulates Dax-1 gene expression during gonadal differentiation. *Mol Cell Biol* **19**, 2289-2299

43 Gao F., Maiti S., Alam N. et al. 2006 The Wilms tumor gene, Wt1, is required for Sox9 expression and maintenance of tubular architecture in the developing testis. *Proc Natl Acad Sci U S A* **103**, 11987-11992

44 Chang H., Gao F., Guillou F. et al. 2008 Wt1 negatively regulates beta-catenin signaling during testis development. *Development* **135**, 1875-1885

45 Chen S.R., Chen M., Wang X.N. et al. 2013 The Wilms tumor gene, Wt1, maintains testicular cord integrity by regulating the expression of Col4a1 and Col4a2. *Biol Reprod* **88**, 56

46 Rao M.K., Pham J., Imam J.S. et al. 2006 Tissue-specific RNAi reveals that WT1 expression in nurse cells controls germ cell survival and spermatogenesis. *Genes Dev* **20**, 147-152

47 Hsu S.Y., Kubo M., Chun S.Y. et al. 1995 Wilms' tumor protein WT1 as an ovarian transcription factor: decreases in expression during follicle development and repression of inhibin-alpha gene promoter. *Mol Endocrinol* **9**, 1356-1366

48 Natoli T.A., Alberta J.A., Bortvin A. et al. 2004 Wt1 functions in the development of germ cells in addition to somatic cell lineages of the testis. *Dev Biol* **268**, 429-440

49 Moore A.W., McInnes L., Kreidberg J. et al. 1999 YAC complementation shows a requirement for Wt1 in the development of epicardium, adrenal gland and throughout nephrogenesis. *Development* **126**, 1845-1857

50 Martínez-Estrada O.M., Lettice L.A., Essafi A. et al. 2010 Wt1 is required for cardiovascular progenitor cell formation through transcriptional control of Snail and E-cadherin. *Nat Genet* **42**, 89-93

51 von Gise A., Zhou B., Honor L.B. et al. 2011 WT1 regulates epicardial epithelial to mesenchymal transition through β -catenin and retinoic acid signaling pathways. *Dev Biol* **356**, 421-431

52 Guadix J.A., Ruiz-Villalba A., Lettice L. et al. 2011 Wt1 controls retinoic acid signalling in embryonic epicardium through transcriptional activation of Raldh2. *Development* **138**, 1093-1097

53 Chen T., Chang T.C., Kang J.O. et al. 2002 Epicardial induction of fetal cardiomyocyte proliferation via a retinoic acid-inducible trophic factor. *Dev Biol* **250**, 198-207

54 Stuckmann I., Evans S., Lassar A.B. 2003 Erythropoietin and retinoic acid, secreted from the epicardium, are required for cardiac myocyte proliferation. *Dev Biol* **255**, 334-349

55 Wagner N., Wagner K.D., Theres H. et al. 2005 Coronary vessel development requires activation of the TrkB neurotrophin receptor by the Wilms' tumor transcription factor Wt1. *Genes Dev* **19**, 2631-2642

56 Kirschner K.M., Wagner N., Wagner K.D. et al. 2006 The Wilms tumor suppressor Wt1 promotes cell adhesion through transcriptional activation of the alpha4integrin gene. *J Biol Chem* **281**, 31930-31939

- 57 Kirschner K.M., Hagen P., Hussels C.S. et al. 2008 The Wilms' tumor suppressor Wt1 activates transcription of the erythropoietin receptor in hematopoietic progenitor cells. *FASEB J* **22**, 2690-2701
- 58 Dame C., Kirschner K.M., Bartz K.V. et al. 2006 Wilms tumor suppressor, Wt1, is a transcriptional activator of the erythropoietin gene. *Blood* **107**, 4282-4290
- 59 Wu H., Lee S.H., Gao J. et al. 1999 Inactivation of erythropoietin leads to defects in cardiac morphogenesis. *Development* **126**, 3597-3605
- 60 Velecela V., Lettice L.A., Chau Y.Y. et al. 2013 WT1 regulates the expression of inhibitory chemokines during heart development. *Hum Mol Genet* **22**, 5083-5095
- 61 Rudat C., Kispert A. 2012 Wt1 and Epicardial Fate Mapping. *Circ Res* **111**,165–169
- 62 Zhou B., Ma Q., Rajagopal S. et al. 2008 Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. *Nature* **454**, 109–113
- 63 Wessels A., van den Hoff M.J.B., Adamo R.F. et al. 2012 Epicardially derived fibroblasts preferentially contribute to the parietal leaflets of the atrioventricular valves in the murine heart. *Dev Biol* **366**,111–124
- 64 Red-Horse K., Ueno H., Weissman I.L. et al. 2010 Coronary arteries form by developmental reprogramming of venous cells. *Nature* **464**, 549–553
- 65 Wu B., Zhang Z., Lui W. et al. 2012 Endocardial cells form the coronary arteries by angiogenesis through myocardial-endocardial VEGF signaling. *Cell* **151**,1083–1096
- 66 Hanson J., Gorman J., Reese J. et al. 2007 Regulation of vascular endothelial growth factor, VEGF, gene promoter by the tumor suppressor, WT1. *Front Biosci* **12**, 2279-2290

67 McCarty G., Awad O., Loeb D.M. 2011 WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. *J Biol Chem* **286**, 43634-43643

68 Vasuri F., Fittipaldi S., Buzzi M. et al. 2012 Nestin and WT1 expression in small-sized vasa vasorum from human normal arteries. *Histol Histopathol* **27**, 1195-1202

69 Kirschner K.M., Sciesielski L.K., Scholz H. et al. 2010 Wilms' tumour protein Wt1 stimulates transcription of the gene encoding vascular endothelial cadherin. *Pflugers Arch* **460**, 1051-1061

70 Zhou B., Pu W.T. 2012 Genetic Cre-loxP assessment of epicardial cell fate using Wt1-driven Cre alleles. *Circ Res* **111**, e276–80

71 King-Underwood L., Little S., Baker M. et al. 2005 Wt1 is not essential for hematopoiesis in the mouse. *Leuk Res* **29**, 803-812

72 Herzer U., Crocoll A., Barton D. et al. 1999 The Wilms tumor suppressor gene wt1 is required for development of the spleen. *Curr Biol* **9**, 837-840

73 Koehler K., Franz T., Dear T.N. et al. 2000 Hox11 is required to maintain normal Wt1 mRNA levels in the developing spleen. *Dev Dyn* **218**, 201-206

74 Wagner K.D., Wagner N., Vidal V.P. et al. 2002 The Wilms' tumor gene Wt1 is required for normal development of the retina. *EMBO J* **21**, 1398-1405

75 Que J., Wilm B., Hasegawa H. et al. 2008 Mesothelium contributes to vascular smooth muscle and mesenchyme during lung development. *Proc Natl Acad Sci U S A* **105**, 16626-16630

- 76 IJpenberg A., Pérez-Pomares J.M., Guadix J.A. et al. 2007 Wt1 and retinoic acid signaling are essential for stellate cell development and liver morphogenesis. *Dev Biol* **312**,157–170
- 77 Asahina K., Zhou B., Pu W.T. et al. 2011 Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. *Hepatology* **53**, 983-995
- 78 Chau Y.Y., Hastie N.D. 2012 The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis. *Trends Genet* **28**, 515-524
- 79 Chau Y.Y., Bandiera R., Serrels A. et al. 2014 Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source. *Nat Cell Biol* **16**, 367-375
- 80 Chau Y.Y., Brownstein D., Mjoseng H. et al. 2011 Acute multiple organ failure in adult mice deleted for the developmental regulator Wt1. *PLoS Genet* **7**, e1002404
- 81 Schumacher V.A., Schlötzer-Schrehardt U., Karumanchi S.A. et al. 2011 WT1-dependent sulfatase expression maintains the normal glomerular filtration barrier. *J Am Soc Nephrol* **22**, 1286-1296
- 82 Karki S., Surolia R., Hock T.D. et al. 2014 Wilms' tumor 1 (Wt1) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in idiopathic pulmonary fibrosis. *FASEB J* **28**, 1122-1131
- 83 Wang X.N., Li Z.S., Ren Y. et al. 2013 The Wilms tumor gene, Wt1, is critical for mouse spermatogenesis via regulation of sertoli cell polarity and is associated with non-obstructive azoospermia in humans. *PLoS Genet* **9**, e1003645

- 84 Zheng Q.S., Wang X.N., Wen Q. et al. 2014 Wt1 deficiency causes undifferentiated spermatogonia accumulation and meiotic progression disruption in neonatal mice. *Reproduction* **147**, 45-52
- 85 Chen M., Wang X., Wang Y. et al. 2014 Wt1 is involved in Leydig cell steroid hormone biosynthesis by regulating paracrine factor expression in mice. *Biol Reprod* **90**, 71
- 86 Wen Q., Zheng Q.S., Li X.X. et al. 2014 Wt1 dictates the fate of fetal and adult Leydig cells during development in the mouse testis. *Am J Physiol Endocrinol Metab* **307**, E1131-1143
- 87 Gao F., Zhang J., Wang X. et al. 2014 Wt1 functions in ovarian follicle development by regulating granulosa cell differentiation. *Hum Mol Genet* **23**, 333-341
- 88 Makrigiannakis A., Amin K., Coukos G. et al. 2000 Regulated expression and potential roles of p53 and Wilms' tumor suppressor gene (WT1) during follicular development in the human ovary. *J Clin Endocrinol Metab* **85**, 449-459
- 89 Makrigiannakis A., Coukos G., Mantani A. et al. 2001 Expression of Wilms' tumor suppressor gene (WT1) in human endometrium: regulation through decidual differentiation. *J Clin Endocrinol Metab* **86**, 5964-5972
- 90 Fraizer G.C., Patmasiriwat P., Zhang X. et al. 1995 Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow. *Blood* **86**, 4704-4706
- 91 Ariyaratana S., Loeb D.M. 2007 The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. *Expert Rev Mol Med* **9**, 1-17
- 92 Inoue K., Tamaki H., Ogawa H. et al. 1998 Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. *Blood* **91**, 2969-2976

93 Tsuboi A., Oka Y., Ogawa H. et al. 1999 Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). *Leuk Res* **23**, 499-505

94 Loeb D.M., Summers J.L., Burwell E.A. et al. 2003 An isoform of the Wilms' tumor suppressor gene potentiates granulocytic differentiation. *Leukemia* **17**, 965-971

95 Ellisen L.W., Carlesso N., Cheng T. et al. 2001 The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. *EMBO J* **20**, 1897-1909

96 Algar E. 2002 A review of the Wilms' tumor 1 gene (WT1) and its role in hematopoiesis and leukemia. *J Hematother Stem Cell Res* **11**, 589-599

97 Hosen N., Shirakata T., Nishida S. et al. 2007 The Wilms' tumor gene WT1-GFP knock-in mouse reveals the dynamic regulation of WT1 expression in normal and leukemic hematopoiesis. *Leukemia* **21**, 1783-1791

98 Alberta J.A., Springett G.M., Rayburn H. et al. 2003 Role of the WT1 tumor suppressor in murine hematopoiesis. *Blood* **101**, 2570-2574

99 Cunningham T.J., Palumbo I., Grosso M. et al. 2011 WT1 regulates murine hematopoiesis via maintenance of VEGF isoform ratio. *Blood* **122**, 188-192

100 Wagner K.D., Wagner N., Bondke A. et al. 2002 The Wilms' tumor suppressor Wt1 is expressed in the coronary vasculature after myocardial infarction. *FASEB J* **16**, 1117-1119

101 Wagner K.D., Wagner N., Wellmann S. et al. 2003 Oxygen-regulated expression of the Wilms' tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1). *FASEB J* **17**, 1364-1366

102 Scholz H., Wagner K.D., Wagner N. 2009 Role of the Wilms' tumour transcription factor, Wt1, in blood vessel formation. *Pflugers Arch* **458**, 315-323

103 Lee S.B., Haber D.A. 2001 Wilms tumor and the WT1 gene. *Exp Cell Res* **264**, 74-99

104 Loeb D.M., Sukumar S. 2002 The role of WT1 in oncogenesis: tumor suppressor or oncogene? *Int J Hematol* **76**, 117-126

105 Brieger J., Weidmann E., Fenchel K. et al. 1994 The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. *Leukemia* **8**, 2138-2143

106 Menssen H.D., Renkl H.J., Rodeck U. et al. 1995 Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. *Leukemia* **9**, 1060-1067

107 Yang L., Han Y., Suarez Saiz F. et al. 2007 A tumor suppressor and oncogene: the WT1 story. *Leukemia* **21**, 868-876

108 Rein L.A., Chao N.J. 2014 WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy. *Expert Opin Investig Drugs* **23**, 417-426

109 Sugiyama H. 2010 WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. *Jpn J Clin Oncol* **40**, 377-387

110 Vasu S., Blum W. 2013 Emerging immunotherapies in older adults with acute myeloid leukemia. *Curr Opin Hematol* **20**, 107-114

111 Carmona R., González-Iriarte M., Pérez-Pomares J.M. et al. 2001 Localization of the Wilm's tumour protein WT1 in avian embryos. *Cell Tissue Res* **303**, 173-186

112 Pérez-Pomares J.M., Phelps A., Sedmerova M. et al. 2002 Experimental studies on the spatiotemporal expression of WT1 and RALDH2 in the embryonic avian heart: a model for the regulation of myocardial and valvuloseptal development by epicardially derived cells (EPDCs). *Dev Biol* **247**, 307-326

113 Schlueter J., Männer J., Brand T. 2006 BMP is an important regulator of proepicardial identity in the chick embryo. *Dev Biol* **295**, 546-558

114 Schulte I., Schlueter J., Abu-Issa R. et al., 2007 Morphological and molecular left-right asymmetries in the development of the proepicardium: a comparative analysis on mouse and chick embryos. *Dev Dyn* **236**, 684-695

115 Ishii Y., Garriock R.J., Navetta A.M. et al. 2007 BMP signals promote proepicardial protrusion necessary for recruitment of coronary vessel and epicardial progenitors to the heart. *Dev Cell* **19**, 307-316

116 Torlopp A, Schlueter J., Brand T. 2010 Role of fibroblast growth factor signaling during proepicardium formation in the chick embryo. *Dev Dyn* **239**, 2393-2403

117 Bollig F., Mehringer R., Perner B. et al. 2006 Identification and comparative expression analysis of a second wt1 gene in zebrafish. *Dev Dyn* **235**, 554-561

118 Bollig F., Perner B., Besenbeck B. et al., 2009 A highly conserved retinoic acid responsive element controls wt1a expression in the zebrafish pronephros. *Development* **136**, 2883-2892

119 Tomar R., Mudumana S.P., Pathak N. et al. 2014 Osr1 is required for podocyte development downstream of wt1a. *J Am Soc Nephrol* **25**, 2539-2545

120 Miles C., Elgar G., Coles E. et al. 1998 Complete sequencing of the Fugu WAGR region from WT1 to PAX6: dramatic compaction and conservation of synteny with human chromosome 11p13. *Proc Natl Acad Sci U S A* **95**, 13068-13072

121 Nakayama Y., Yamamoto T., Matsuda Y. et al. 1998 Cloning of cDNA for newt WT1 and the differential expression during spermatogenesis of the Japanese newt, *Cynops pyrrhogaster*. *Dev Growth Differ* **40**, 599-608

122 Semba K., Saito-Ueno R., Takayama G. et al. 1996 cDNA cloning and its pronephros-specific expression of the Wilms' tumor suppressor gene, WT1, from *Xenopus laevis*. *Gene* **175**, 167-172

123 Carroll T.J., Vize P.D. 1996 Wilms' tumor suppressor gene is involved in the development of disparate kidney forms: evidence from expression in the *Xenopus* pronephros. *Dev Dyn* **206**, 131-138

124 Wallingford J.B., Carroll T.J., Vize P.D. et al. 1998 Precocious expression of the Wilms' tumor gene xWT1 inhibits embryonic kidney development in *Xenopus laevis*. *Dev Biol* **202**, 103-112

- 125 Shimeld S.M. 2008 C2H2 zinc finger genes of the Gli, Zic, KLF, SP, Wilms' tumour, Hucbein, Snail, Ovo, Spalt, Odd, Blimp-1, Fez and related gene families from *Branchiostoma floridae*. *Dev Genes Evol* **218**, 639-649
- 126 Losada-Pérez M., Gabilondo H., Molina I. 2013 Klumpfuss controls FMRamide expression by enabling BMP signaling within the NB5-6 lineage. *Development* **140**, 2181-2189
- 127 Gabilondo H., Losada-Pérez M., Monedero I. et al. 2014 A new role of Klumpfuss in establishing cell fate during the GMC asymmetric cell division. *Cell Tissue Res* **358**, 621-626
- 128 Terriente-Felix A., Li J., Collins S., Mulligan A. et al. 2013 Notch cooperates with Lozenge/Runx to lock haemocytes into a differentiation programme. *Development* **140**, 926-937